RE:Market learning to differentiateOnly VRX has a investigation. CXR has nothing to do with that. This is the proof.
NEW YORK, NY / ACCESSWIRE / October 22, 2015 / Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Valeant Pharmaceuticals International, Inc.("Valeant" or the "Company") (NYSE: VRX). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. digitel wrote: Valeant down 15.2% and Concordia down 2%.